Popular Articles From: PDF Solutions(R) Reports Third Fiscal Quarter 2014 Results to Philips Zoom QuickPro Brings Consumers Ultimate Convenience with First Ever Five-Minute, In-Office Professional Whitening Treatment


SAN JOSE, Calif., Oct.
Sign-up for PDF Solutions(R) Reports Third Fiscal Quarter 2014 Results investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today reported that the U.S. Food and Drug Administration (FDA) has extended the company’s Prescription Drug User Fee Act (PDUFA) action date for its Natpara Biologics License Application (BLA) by three months from October 24, 2014 to January 24, 2015.
Sign-up for PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015 investment picks
Pebblebrook Hotel Trust (NYSE:PEB) (the “Company”) today announced that it has acquired The Westin Colonnade Coral Gables (“The Westin Colonnade”) for $59.4 million.
Sign-up for Pebblebrook Hotel Trust Acquires The Westin Colonnade Coral Gables in Miami, Florida investment picks
Pebblebrook Hotel Trust (the “Company”) (NYSE: PEB) announced today that it intends to issue 3,200,000 of its common shares of beneficial interest, $0.01 par value per share, in an underwritten public offering.
Sign-up for Pebblebrook Hotel Trust Announces Public Offering of 3,200,000 Common Shares investment picks
http://media.marketwire.com/attachments/201410/81087_PegaLogoBLACKCYAN_resize2.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1154751&ProfileId=051205&sourceType=1 CAMBRIDGE, MA --
Sign-up for Pegasystems Raises the Bar for Customer Experience With Latest Industry-Leading Customer Service Application investment picks
2014/11/11
Pembina Pipeline Corporation Announces November 2014 Dividend Canada NewsWire CALGARY , Nov.
Sign-up for Pembina Pipeline Corporation Announces November 2014 Dividend investment picks
2014/11/11
CALGARY , Nov.
Sign-up for Pembina Pipeline Corporation Announces November 2014 Dividend investment picks
2014/11/17
Penn West Announces Details of its 2015 Capital Budget and Long-Term Plan Update Canada NewsWire LONG-TERM PLAN UPDATE Penn West's Long-Term Plan remains centered on reliability and deliverability of operational performance, key components of which are effective cost control and development, including integrated waterflood support concentrated in our large, light oil resource plays.
Sign-up for Penn West Announces Details of its 2015 Capital Budget and Long-Term Plan Update investment picks
2014/11/17
CALGARY , Nov.
Sign-up for Penn West Announces Details of its 2015 Capital Budget and Long-Term Plan Update investment picks
Successful Appeal of the Tincher Ruling is the Company's Fifth Consecutive Legal Victory MIDDLETOWN, Conn., Dec.
Sign-up for Pennsylvania Supreme Court Rules in Favor of Omega Flex in Striking Down the State's Broad Liability Law and Vacating the Jury's Ruling in the Tincher Case investment picks
Estimated Annual Incremental Earnings per Share of $0.12 to $0.14 BLOOMFIELD HILLS, Mich.
Sign-up for Penske Automotive Completes Acquisition Of Heavy-Duty Truck Dealership Group investment picks
New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital ABBOTT PARK, Ill., Nov.
Sign-up for People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes investment picks
http://media.marketwire.com/attachments/201406/258111_Performancelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161043&ProfileId=051205&sourceType=1 EXETER, NH --
Sign-up for Performance Sports Group Addresses Pending NOCSAE Lacrosse Notification investment picks
2014/10/3
By Sital S.
Sign-up for Peter Thiel's Wish list investment picks
2014/10/21
LAFAYETTE, La.
Sign-up for PetroQuest Energy, Inc. Invites You To Join Its 2014 Third Quarter Earnings Conference Call investment picks
2014/11/5
OR YEHUDA, Israel , November 5, 2014 /PRNewswire/ -- Magic Software Enterprises Ltd.
Sign-up for Petzl, Leading Manufacturer of Equipment for Sports and Work at Height, Selects Magic xpi Integration Platform for Business Process Automation investment picks
Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease.
Sign-up for Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review investment picks
Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.
Sign-up for Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology investment picks
Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ ® (tofacitinib citrate) will be presented, including the six-year safety and efficacy analyses from long-term extension (LTE) studies and a summary of real-world patient experience, additional post-hoc analyses from the clinical development program, and health and economics outcomes research, adding to the substantial body of evidence for XELJANZ as an oral treatment option for moderate to severe rheumatoid arthritis (RA). Data will also be presented for several additional Pfizer assets, including PF-04236921, an investigational
Sign-up for Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting investment picks
2014/11/3
Key Supply Relationships Help PG&E Deliver for Customers While Supporting Job Creation and Economic Vitality SAN FRANCISCO , Nov.
Sign-up for PG&E Honors Six Leading Business Partners at Ninth Annual Supplier Awards investment picks
SAN FRANCISCO , Oct.
Sign-up for PG&E Self-Reports Additional Emails To CPUC investment picks
Prestigious international competition tests safety and technical skills among more than 200 elite teams from the United States, Canada and the United Kingdom GRASS VALLEY, Calif.
Sign-up for PG&E Team Wins Championship Honors In 2014 International Lineman's Rodeo investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today announced that it has completed the acquisition of Millennium Pharmacy Systems (“Millennium”). Millennium is a pharmacy services provider to the long-term care industry that operates seven institutional pharmacies primarily in the Mid-Atlantic region.
Sign-up for PharMerica Acquires Millennium Pharmacy Systems investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached.
Sign-up for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks
Pfizer Inc. (NYSE:PFE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine .
Sign-up for Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer investment picks
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will be presented at the United European Gastroenterology Week in Vienna, Austria.
Sign-up for Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 investment picks
2014/11/5
Philips eICU Program now provides telehealth-enabled support for veterans across 2,000 miles ANDOVER, Mass.
Sign-up for Philips helps the Veterans Health Administration expand access to 24x7 intensivist care from hospital to home investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Popular Articles From: PDF Solutions(R) Reports Third Fiscal Quarter 2014 Results to Philips Zoom QuickPro Brings Consumers Ultimate Convenience with First Ever Five-Minute, In-Office Professional Whitening Treatment
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent